Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential <em>SARS-CoV-2</em> Viral Inhibitors
Unfortunately, to date, there is no approved specific antiviral drug treatment against COVID-19. Due to the costly and time-consuming nature of the de novo drug discovery and development process, in recent days, the computational drug repositioning method has been highly regarded for accelerating th...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/79878 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential <em>SARS-CoV-2</em> Viral Inhibitors
- Repurposing Drugs as Potential Therapeutics for the SARS-Cov-2 Viral Infection: Automatizing a Blind Molecular Docking High-throughput Pipeline
- Role of Anti-Viral Drugs in Combating SARS-CoV-2
- Applications of Molecular Docking Studies in SARS-CoV-2 Targeted Drug Discovery and the Gains Achieved through Molecular Docking
- The influence of SARS-COV-2 pandemic in the pharmaceutical service in ALBANIA
- SARS-CoV-2 Mutation Mechanism, Features, and Future Perspective
- Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates